Clayton Kersting, MD
Family Medicine · Newport, WANPI 1962594234
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,863 of the $16,880 with a category attached, or 94.0%. Organon accounts for 70.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $7,642 and has fallen 99.8% since, to $14 in 2025. Among family medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $219.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$12K
- Merck$4K
- Johnson & Johnson$81
- Boehringer Ingelheim$77
- Sanofi-aventis U.S. LLC$73
- AbbVie$50
- plus $326 from 13 others
What the payments were for
- Speaking & faculty fees$15,86394%
- Travel & lodging$2712%
- Food & beverage$7454%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 19 | $11,974 |
| Merck | 15 | $4,298 |
| Johnson & Johnson | 6 | $81 |
| Boehringer Ingelheim | 5 | $77 |
| Sanofi-aventis U.S. LLC | 6 | $73 |
| AbbVie | 3 | $50 |
| Novo Nordisk | 4 | $49 |
| Lilly USA, LLC | 3 | $45 |
| Gilead | 2 | $36 |
| GSK | 3 | $34 |
| Amgen | 2 | $33 |
| Astellas Pharma US Inc | 2 | $31 |
| Novartis | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Abbott | 1 | $11 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$15,542
How this compares
$16,880 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 14 | $42,797 |
| OzempicSemaglutide | 36 | $41,714 |
| JardianceEmpagliflozin | 23 | $27,746 |
| EliquisApixaban | 43 | $21,353 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $14,566 |
| MounjaroTirzepatide | 13 | $13,977 |
| XareltoRivaroxaban | 19 | $10,529 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $10,346 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $9,944 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $5,829 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,577 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 184 | $5,246 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,039 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $4,197 |
| Testosterone | 12 | $4,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $49 | $41,71436 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $77 | $32,78434 claims |
| PfizerEliquis | $11 | $21,35343 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $34 | $20,39527 claims |
| Lilly USA, LLCMounjaro | $45 | $13,97713 claims |
| Johnson & JohnsonXarelto | $81 | $10,52919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Newport
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
- Cynthia CoteMaple Valley$66K
- Greg LedgerwoodBrewster$66K
- Daniel RivasBurien$50K
- Kent WalkerSumner$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.